Applied public-private research enabling osteoarthritis clinical headway


Start Date
End Date
IMI1 - Call 11
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
7 500 000
EFPIA in kind
7 580 423
2 273 050
Total Cost
17 353 473


Some 9.6% of men and 18% of women over 60 suffer from osteoarthritis, and a quarter of those affected struggle to carry out ordinary daily activities. However, developing effective treatments for this debilitating condition is extremely challenging. The APPROACH project is creating a platform comprising data on over 10 000 patients and healthy people. The project team will use this data to identify groups of patients with similar profiles; these groups could respond well to specific treatments. This information will ultimately be used to identify patients who could take part in clinical trials of more personalised treatments for osteoarthritis.

The burden of the disease is increasing yet there is no cure

It is estimated that 9.6% of men and 18% of women over the age of 60 worldwide experience the debilitating symptoms of osteoarthritis. As people tend to live longer, and the population of people over 60 is increasing, cases of the disease are on the rise. Direct and indirect costs of osteoarthritis in the EU are already substantial: in the UK alone, total costs for adaptive aids and devices, medicines, surgery and time off work are estimated to be equivalent to 1% of the gross national product per year. The burden will be greatest in developing countries, where life expectancy is increasing and access to arthroplasty and joint replacement is not readily available. Furthermore, although there are a wide range of devices and palliative medicines available that can relieve pain and improve quality of life, there are currently no pharmaceutical products that can halt or reverse the onset of osteoarthritis.

Despite the large and growing burden of this disease, many pharmaceutical companies have reduced or altogether abandoned drug development. One of the problems is that there are currently no reliable ways of measuring whether a specific treatment is working or not. This is partly because the mechanisms which lead to the disease in different subgroups of patients are poorly understood. Moreover, although the current mind-set for treatment in this field is moving towards personalised medicine, there are no accepted methods of classifying the patients according to diagnosis methodology, prognosis and treatment plan. It is clear that a better understanding of the disease is urgently needed.

Complex algorithms to hunt for disease subtypes

By bringing together a strong team of 25 partners from European clinical centres, basic research institutes, small and medium-sized enterprises (SMEs) and pharmaceutical companies, the APPROACH consortium will combine biomedical data of more than 10 000 patients and heathy people from 8 existing cohorts into a unified bioinformatics platform. With the help of complex algorithms, bioinformaticians will comb through this central database to identify subtypes or phenotypes of osteoarthritis. These subtypes will then be validated in a longitudinal clinical study, using existing and newly-developed biological markers. Ultimately, the identification of subtypes of this disease should lead to improved drug development and diagnostic tools, allowing osteoarthritis patients to receive better, more personalised treatment.

The project will focus on knee osteoarthritis – a very common form of osteoarthritis which is a major cause of impaired mobility (particularly in women) and therefore has a high clinical burden. This form of the disease is ideal for the APPROACH database because it has been extensively examined in large groups of patients and lots of standardised data, such as x-ray and MRI measurements, is available.

Valuable tools and outcomes

At the end of the project, APPROACH will provide valuable tools, methods and definitions that will be used to optimise future clinical trials for osteoarthritis, paving the way for personalised medicine. More specifically, the main outcomes of the project will be as follows:

  • an integrated bioinformatics platform which functions as a repository for clinical data, biomarker data, images, as well as storage of bio-tissues from a broad spectrum of osteoarthritis patients;
  • subsets of patients based on well-defined subtypes or phenotypes of the disease;
  • new biological markers for osteoarthritis based on imaging, locomotion and biochemical methods;
  • validation and optimisation of the next generation imaging methodologies, human motion analysis and biochemical methods to enable more efficient diagnosis and treatment of osteoarthritis patients.

A big step towards more personalised medicine for patients

By identifying different subtypes of osteoarthritis, APPROACH will make a big step forward in helping the pharmaceutical companies develop more effective treatments for the osteoarthritis patients. Patients will reap the greatest benefits as the identification of disease subtypes will lead to improved diagnostic tools and more effective, highly personalised treatments.

Achievements & News

APPROACH screens first patient
January 2018

IMI osteoarthritis project APPROACH has screened the first patient in a clinical study on osteoarthritis of the knee that will pave the way for more personalised treatments for the disease. Over the next two years, 300 patients across Europe will undergo assessments on pain, mobility, cartilage and bone condition, and inflammation. ###Information gathered will help the project to identify biological markers (biomarkers) of disease progression. ‘Currently, all osteoarthritis patients are treated the same. The quality of clinical trials and personalised treatments by doctors will improve tremendously when disease subtypes can be diagnosed. Biomarkers will help to push this forward,’ said Anne Karien Marijnissen, coordinator of the APPROACH clinical study. The project’s seven-strong Patient Council was influential in the set up of the clinical study, collaborating on communications and study design (especially with reference to the burden on study participants) and reviewing the research protocol and patient informed consent forms.

Participants Show participants on map

EFPIA companies
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Institut De Recherches Internationales Servier Iris, Suresnes, France
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Arthritis Research UK, Chesterfield, United Kingdom
  • Assistance Publique Hopitaux De Paris, Paris, France
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Diakonhjemmet Sykehus As, Oslo, Norway
  • Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Erlangen, Germany
  • Lunds Universitet, Lund, Sweden
  • Oulun Yliopisto, Oulu, Finland
  • Servizo Galego De Saude, Santiago de Compostela, Spain
  • Stichting Lygature, Utrecht, Netherlands
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universitatsklinikum Erlangen, Erlangen, Germany
  • University Of Leeds, Leeds, United Kingdom
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs)
  • Artialis SA, Liège (Sart-Tilman), Belgium
  • Nordic Bioscience Compound Development A/S, Herlev, Denmark
Patient organisations
  • Stichting Nationaal Reumafonds, Amsterdam, Netherlands
Third parties
  • Universite Paris Diderot - Paris 7, Paris, France
Non EFPIA companies
  • Immunodiagnostic Systems Holdings PLC, Boldon, United Kingdom
Project coordinator
Jonathan Larkin
Glaxosmithkline Research And Development LTD
United States
Managing entity
Harrie Weinans
University Medical Center Utrecht